MarcoBerndMielcarekMD

Oncology • Seattle, WA

Associate Professor, Medicine, University of Washington School of Medicine

Join to view full profile

Are you Dr. Mielcarek?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 21 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
Ambulatory Clinic
825 Eastlake Avenue East
Seattle, WA 98109
Phone+1 206-288-1000

Summary

Dr. Marco Mielcarek, MD is an oncologist in Seattle, Washington. He is currently licensed to practice medicine in Washington, Montana, and Hawaii. He is affiliated with Fred Hutch Cancer Center and UW Medicine/University of Washington Medical Center.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2000 - 2003
University of WashingtonResidency, Internal Medicine, 1998 - 2001
Freie University Berlin Faculty of MedicineClass of 1986

Certifications & Licensure

MT State Medical License 2022 - 2026
WA State Medical License 2000 - 2025
HI State Medical License 2018 - 2024
American Board of Internal Medicine Medical Oncology

Clinical Trials

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma Start of enrollment: 2002 Oct 01
Completed
Phase 1, Phase 2
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Start of enrollment: 2006 May 01
Completed
Phase 2
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma Start of enrollment: 2008 Oct 01
Completed
Phase 2
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Start of enrollment: 2011 Sep 01
Completed
Phase 2
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation Start of enrollment: 2012 May 01
Completed
Phase 2
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Start of enrollment: 2012 Sep 25
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics.
Emily A Rosen, Elizabeth M Krantz, Denise J McCulloch, Marie H Wilson, Frank Tverdek
Transplantation and Cellular Therapy. 2024-11-01
1 citations
The Effect of Gastrointestinal Graft-Versus-Host Disease and Diarrhea on the Pharmacokinetic Profile of Sotrovimab in Hematopoietic Stem Cell Transplant Recipients.
Jim Boonyaratanakornkit, Qianwen Wang, Ahmed Nader, Louise Kimball, Terry Stevens-Ayers
The Journal of Infectious Diseases. 2024-09-23
1 citations
Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization.
Andrew J Portuguese, Albert C Yeh, Rahul Banerjee, Leona Holmberg, Natalie Wuliji
Transplantation and Cellular Therapy. 2024-08-01

Press Mentions

Patients Navigate Cancer During COVID-19 PandemicOctober 13th, 2020
How to Exceed 5-Year Post-Transplant Survival in the U.S.May 5th, 2018
Fred Hutch Doctor Takes on Life-Threatening Stem Cell Transplant ComplicationFebruary 13th, 2017
Join now to see all

Other Languages

German